{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:29:34Z","timestamp":1791289774891,"version":"4.3.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/mop.0b013e32835df4a3","type":"journal-article","created":{"date-parts":[[2013,2,16]],"date-time":"2013-02-16T11:38:34Z","timestamp":1361014714000},"page":"225-231","source":"Crossref","is-referenced-by-count":32,"title":["Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases"],"prefix":"10.1097","volume":"25","author":[{"given":"Carla M.","family":"Nester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick D.","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210206","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.","volume":"350","author":"Hillmen","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-13-20210206","first-page":"A668","article-title":"Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy.","volume":"13","author":"Appel","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R3-13-20210206","first-page":"1017","article-title":"Eculizumab (Alexion).","volume":"3","author":"Kaplan","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"R4-13-20210206","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome.","volume":"360","author":"Gruppo","year":"2009","journal-title":"N Engl J Med"},{"key":"R5-13-20210206","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic-uremic syndrome.","volume":"360","author":"Nurnberger","year":"2009","journal-title":"N Engl J Med"},{"key":"R6-13-20210206","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome.","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"key":"R7-13-20210206","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R8-13-20210206","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"R9-13-20210206","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","article-title":"Complement and the atypical hemolytic uremic syndrome in children.","volume":"23","author":"Loirat","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"R10-13-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2007.03552.x","article-title":"Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H.","volume":"151","author":"de Cordoba","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"R11-13-20210206","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome.","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int"},{"key":"R12-13-20210206","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/humu.20435","article-title":"The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.","volume":"28","author":"Saunders","year":"2007","journal-title":"Hum Mutat"},{"key":"R13-13-20210206","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2009-01-197640","article-title":"Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome.","volume":"114","author":"Roumenina","year":"2009","journal-title":"Blood"},{"key":"R14-13-20210206","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00467-009-1415-3","article-title":"A novel mutation in the complement factor B gene (CFB) and atypical hemolytic uremic syndrome.","volume":"25","author":"Tawadrous","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"R15-13-20210206","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.","volume":"112","author":"Fremeaux-Bacchi","year":"2008","journal-title":"Blood"},{"key":"R16-13-20210206","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.2215\/CJN.06281208","article-title":"A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure.","volume":"4","author":"Lhotta","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R17-13-20210206","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1136\/jmg.2004.019083","article-title":"Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome.","volume":"41","author":"Fremeaux-Bacchi","year":"2004","journal-title":"J Med Genet"},{"key":"R18-13-20210206","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1681\/ASN.2005010103","article-title":"Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.","volume":"16","author":"Kavanagh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R19-13-20210206","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2007.05.004","article-title":"Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome.","volume":"45","author":"Kavanagh","year":"2008","journal-title":"Mol Immunol"},{"key":"R20-13-20210206","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/eji.200939280","article-title":"Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I.","volume":"40","author":"Nilsson","year":"2010","journal-title":"Eur J Immunol"},{"key":"R21-13-20210206","doi-asserted-by":"crossref","first-page":"12966","DOI":"10.1073\/pnas.2135497100","article-title":"Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.","volume":"100","author":"Richards","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R22-13-20210206","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/S0140-6736(03)14742-3","article-title":"Familial haemolytic uraemic syndrome and an MCP mutation.","volume":"362","author":"Noris","year":"2003","journal-title":"Lancet"},{"key":"R23-13-20210206","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic uremic syndrome.","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"R24-13-20210206","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1371\/journal.pgen.0030041","article-title":"Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome.","volume":"3","author":"Zipfel","year":"2007","journal-title":"PLoS Genet"},{"key":"R25-13-20210206","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jmg.2008.064766","article-title":"The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.","volume":"46","author":"Dragon-Durey","year":"2009","journal-title":"J Med Genet"},{"key":"R26-13-20210206","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"R27-13-20210206","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","article-title":"Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1CFHR3 deficiency.","volume":"111","author":"Jozsi","year":"2008","journal-title":"Blood"},{"key":"R28-13-20210206","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrneph.2010.85","article-title":"C3 glomerulopathy: a new classification.","volume":"6","author":"Fakhouri","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"R29-13-20210206","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jmg.2006.045328","article-title":"Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.","volume":"44","author":"Servais","year":"2007","journal-title":"J Med Genet"},{"key":"R30-13-20210206","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1681\/ASN.2005010078","article-title":"Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.","volume":"16","author":"Appel","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R31-13-20210206","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/modpathol.3800773","article-title":"Dense deposit disease is not a membranoproliferative glomerulonephritis.","volume":"20","author":"Walker","year":"2007","journal-title":"Mod Pathol"},{"key":"R32-13-20210206","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ki.1986.278","article-title":"H deficiency in two brothers with atypical dense intramembranous deposit disease.","volume":"30","author":"Levy","year":"1986","journal-title":"Kidney Int"},{"key":"R33-13-20210206","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/01.ASN.0000115702.28859.A7","article-title":"Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases.","volume":"15","author":"Dragon-Durey","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R34-13-20210206","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.ki.5000269","article-title":"Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II).","volume":"70","author":"Licht","year":"2006","journal-title":"Kidney Int"},{"key":"R35-13-20210206","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1172\/JCI43343","article-title":"Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.","volume":"120","author":"Martinez-Barricarte","year":"2010","journal-title":"J Clin Invest"},{"key":"R36-13-20210206","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.2215\/CJN.09541010","article-title":"Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees.","volume":"6","author":"Athanasiou","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R37-13-20210206","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ajkd.2012.02.329","article-title":"Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency.","volume":"60","author":"Vernon","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"R38-13-20210206","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"R39-13-20210206","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1073\/pnas.0601094103","article-title":"Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice.","volume":"103","author":"Pickering","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R40-13-20210206","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMc1111953","article-title":"Eculizumab for the treatment of dense-deposit disease.","volume":"366","author":"Vivarelli","year":"2012","journal-title":"N Engl J Med"},{"key":"R41-13-20210206","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMc1112273","article-title":"Eculizumab in a patient with dense-deposit disease.","volume":"366","author":"Daina","year":"2012","journal-title":"N Engl J Med"},{"key":"R42-13-20210206","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1600-6143.2011.03923.x","article-title":"Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies.","volume":"12","author":"McCaughan","year":"2012","journal-title":"Am J Transplant"},{"key":"R43-13-20210206","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis.","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R44-13-20210206","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe shiga-toxin-associated HUS.","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"key":"R45-13-20210206","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry.","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R46-13-20210206","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study.","volume":"345","author":"Menne","year":"2012","journal-title":"BMJ"},{"key":"R47-13-20210206","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2249.1991.tb02954.x","article-title":"Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection.","volume":"86","author":"Feucht","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"R48-13-20210206","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/j.1600-6143.2008.02441.x","article-title":"Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation.","volume":"8","author":"Burns","year":"2008","journal-title":"Am J Transplant"},{"key":"R49-13-20210206","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"key":"R50-13-20210206","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJMc1106619","article-title":"Eculizumab and refractory membranoproliferative glomerulonephritis.","volume":"366","author":"Radhakrishnan","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0b013e32835df4a3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:42:52Z","timestamp":1620963772000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201304000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0b013e32835df4a3","relation":{},"ISSN":["1040-8703"],"issn-type":[{"value":"1040-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}